You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlfuzosin
Accession NumberDB00346  (APRD00490)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAlfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]
Structure
Thumb
Synonyms
(±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide
Alfuzosin
Alfuzosina
Alfuzosine
Alfuzosinum
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
External Identifiers
  • SL 77499-10
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alfuzosintablet (extended-release)10 mgoralPro Doc Limitee2013-11-21Not applicableCanada
Alfuzosintablet (extended-release)10 mgoralSivem Pharmaceuticals Ulc2015-11-25Not applicableCanada
Auro-alfuzosintablet (extended-release)10 mgoralAuro Pharma Inc2015-09-02Not applicableCanada
Sandoz Alfuzosintablet (extended-release)10 mgoralSandoz Canada Incorporated2008-08-28Not applicableCanada
Teva-alfuzosin Prtablet (extended-release)10 mgoralTeva Canada Limited2010-08-31Not applicableCanada
Uroxatraltablet, extended release10 mg/1oralSanofi Aventis U.S. Llc2009-06-05Not applicableUs
Uroxatraltablet, extended release10 mg/1oralConcordia Pharmaceuticals Inc.2013-06-03Not applicableUs
Uroxatraltablet, extended release10 mg/1oralStat Rx USA2009-06-05Not applicableUs
Uroxatraltablet, extended release10 mg/1oralCovis Pharmaceuticals Inc.2013-06-03Not applicableUs
Uroxatraltablet, extended release10 mg/1oralPhysicians Total Care, Inc.2004-06-22Not applicableUs
Xatraltablet (extended-release)10 mgoralSanofi Aventis Canada Inc2002-02-21Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alfuzosin Hydrochloridetablet10 mg/1oralWockhardt Limited2012-08-15Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralMylan Pharmaceuticals Inc.2011-08-09Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralDIRECT RX2015-12-21Not applicableUs
Alfuzosin Hydrochloridetablet, film coated, extended release10 mg/1oralCitron Pharma LLC2012-08-30Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-03-15Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralTorrent Pharmaceuticals Limited2011-07-18Not applicableUs
Alfuzosin Hydrochloridetablet10 mg/1oralWockhardt USA LLC.2012-08-15Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralSun Pharma Global FZE2011-11-22Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralGolden State Medical Supply, Inc.2011-07-18Not applicableUs
Alfuzosin Hydrochloridetablet, film coated, extended release10 mg/1oralAurobindo Pharma Limited2012-08-30Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralPhysicians Total Care, Inc.2012-02-22Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralApotex Corp.2011-07-18Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralAidarex Pharmaceuticals LLC2011-11-22Not applicableUs
Alfuzosin Hydrochloridetablet, extended release10 mg/1oralExelan Pharmaceuticals Inc.2012-10-02Not applicableUs
Alfuzosin Hydrochloride ERtablet, extended release10 mg/1oralAv Kare, Inc.2012-03-13Not applicableUs
Alfuzosin Hydrochloride Extended Releasetablet10 mg/1oralCamber Pharmaceuticals2012-01-18Not applicableUs
Apo-alfuzosintablet (extended-release)10 mgoralApotex Inc2008-08-20Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlcininPharmathen
Alfasin XRIncepta
AlfetimSanofi-Aventis
AlfooDr. Reddy's
AlfuRowex
AlfuranTerapia
AlfusozinaGrey Inversiones
FlotralRanbaxy
FualAlkem
ProfuzoNeiss
RantralRanbaxy
UritenSquare
XantralSanofi-Aventis
XelfloSun
ZatralEskayef
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Alfuzosin Hydrochloride
ThumbNot applicableDBSALT001063
Categories
UNII90347YTW5F
CAS number81403-80-7
WeightAverage: 389.4488
Monoisotopic: 389.206304377
Chemical FormulaC19H27N5O4
InChI KeyInChIKey=WNMJYKCGWZFFKR-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
IUPAC Name
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolinamines
Alternative Parents
Substituents
  • Quinazolinamine
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Saccharide
  • Heteroaromatic compound
  • Oxolane
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
PharmacodynamicsAlfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha(1) subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha(1) agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1a adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha(1) agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.
Mechanism of actionAlfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Related Articles
AbsorptionAbsorption is 50% lower under fasting conditions
Volume of distribution
  • 3.2 L/kg [healthy male middle-aged volunteers]
Protein binding82%-90%
Metabolism

Hepatic. Alfuzosin undergoes extensive metabolism by the liver, with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by three metabolic pathways: oxidation, O-demethylations, and N-dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.

Route of eliminationFollowing oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine.
Half life10 hours
ClearanceNot Available
ToxicitySide effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6215
Caco-2 permeable-0.5504
P-glycoprotein substrateSubstrate0.8105
P-glycoprotein inhibitor IInhibitor0.5971
P-glycoprotein inhibitor IINon-inhibitor0.5479
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.8722
CYP450 2D6 substrateNon-substrate0.7748
CYP450 3A4 substrateSubstrate0.7766
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8017
Ames testNon AMES toxic0.559
CarcinogenicityNon-carcinogens0.8721
BiodegradationNot ready biodegradable0.9945
Rat acute toxicity2.6826 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8527
hERG inhibition (predictor II)Inhibitor0.5929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseoral10 mg/1
Tabletoral10 mg/1
Tablet, extended releaseoral10 mg/1
Tablet (extended-release)oral10 mg
Prices
Unit descriptionCostUnit
Uroxatral 10 mg 24 Hour tablet4.06USD tablet
Uroxatral 10 mg tablet3.95USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2264250 No2005-07-052017-08-22Canada
US4661491 No1994-01-182011-01-18Us
US6149940 Yes1998-02-222018-02-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.282 mg/mLALOGPS
logP2.02ALOGPS
logP1.19ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.64ChemAxon
pKa (Strongest Basic)7.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.83 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.11 m3·mol-1ChemAxon
Polarizability42.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Mathias Scheer, “Alfuzosin tablets and synthesis.” U.S. Patent US20060062845, issued March 23, 2006.

US20060062845
General References
  1. McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. [PubMed:11893233 ]
  2. Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. [PubMed:7682910 ]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  4. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  5. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
External Links
ATC CodesG04CA51G04CA01
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (72.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Alfuzosin can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Alfuzosin can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Alfuzosin can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
AcebutololAlfuzosin may increase the hypotensive activities of Acebutolol.
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Alfuzosin.
AliskirenAlfuzosin may increase the hypotensive activities of Aliskiren.
AlogliptinThe serum concentration of Alfuzosin can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Alfuzosin can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprenololAlfuzosin may increase the hypotensive activities of Alprenolol.
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Alfuzosin.
AmbrisentanAlfuzosin may increase the hypotensive activities of Ambrisentan.
AmiodaroneThe serum concentration of Alfuzosin can be increased when it is combined with Amiodarone.
AmiodaroneAlfuzosin may increase the QTc-prolonging activities of Amiodarone.
AmlodipineAlfuzosin may increase the hypotensive activities of Amlodipine.
AmprenavirThe serum concentration of Alfuzosin can be increased when it is combined with Amprenavir.
AmrinoneAlfuzosin may increase the hypotensive activities of Amrinone.
AnagrelideAlfuzosin may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Alfuzosin can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Alfuzosin can be increased when it is combined with Apixaban.
AprepitantThe serum concentration of Alfuzosin can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Alfuzosin can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Alfuzosin can be increased when it is combined with Argatroban.
ArotinololArotinolol may increase the orthostatic hypotensive activities of Alfuzosin.
Arsenic trioxideAlfuzosin may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherAlfuzosin may increase the QTc-prolonging activities of Artemether.
AsenapineAlfuzosin may increase the QTc-prolonging activities of Asenapine.
AsunaprevirThe serum concentration of Alfuzosin can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Alfuzosin can be increased when it is combined with Atazanavir.
AtenololAlfuzosin may increase the hypotensive activities of Atenolol.
AtenololAtenolol may increase the orthostatic hypotensive activities of Alfuzosin.
AtomoxetineThe metabolism of Alfuzosin can be decreased when combined with Atomoxetine.
AzelnidipineAlfuzosin may increase the hypotensive activities of Azelnidipine.
AzimilideAlfuzosin may increase the hypotensive activities of Azimilide.
AzithromycinAlfuzosin may increase the QTc-prolonging activities of Azithromycin.
BarnidipineAlfuzosin may increase the hypotensive activities of Barnidipine.
BatimastatThe serum concentration of Alfuzosin can be increased when it is combined with Batimastat.
BedaquilineAlfuzosin may increase the QTc-prolonging activities of Bedaquiline.
BefunololBefunolol may increase the orthostatic hypotensive activities of Alfuzosin.
BenazeprilAlfuzosin may increase the hypotensive activities of Benazepril.
BenazeprilThe serum concentration of Alfuzosin can be increased when it is combined with Benazepril.
BendroflumethiazideAlfuzosin may increase the hypotensive activities of Bendroflumethiazide.
BenidipineAlfuzosin may increase the hypotensive activities of Benidipine.
BenzamidineThe serum concentration of Alfuzosin can be increased when it is combined with Benzamidine.
BepridilAlfuzosin may increase the hypotensive activities of Bepridil.
BetaxololAlfuzosin may increase the hypotensive activities of Betaxolol.
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Alfuzosin.
BethanidineAlfuzosin may increase the hypotensive activities of Bethanidine.
BevantololBevantolol may increase the orthostatic hypotensive activities of Alfuzosin.
BexaroteneThe serum concentration of Alfuzosin can be decreased when it is combined with Bexarotene.
BimatoprostAlfuzosin may increase the hypotensive activities of Bimatoprost.
BisoprololAlfuzosin may increase the hypotensive activities of Bisoprolol.
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Alfuzosin.
BivalirudinThe serum concentration of Alfuzosin can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Alfuzosin can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the orthostatic hypotensive activities of Alfuzosin.
BortezomibThe metabolism of Alfuzosin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Alfuzosin can be decreased when it is combined with Bosentan.
BosentanAlfuzosin may increase the hypotensive activities of Bosentan.
BretyliumAlfuzosin may increase the hypotensive activities of Bretylium.
BrimonidineAlfuzosin may increase the hypotensive activities of Brimonidine.
BufuralolBufuralol may increase the orthostatic hypotensive activities of Alfuzosin.
BupranololAlfuzosin may increase the hypotensive activities of Bupranolol.
BupranololBupranolol may increase the orthostatic hypotensive activities of Alfuzosin.
CandesartanAlfuzosin may increase the hypotensive activities of Candesartan.
CandoxatrilAlfuzosin may increase the hypotensive activities of Candoxatril.
CandoxatrilThe serum concentration of Alfuzosin can be increased when it is combined with Candoxatril.
CaptoprilAlfuzosin may increase the hypotensive activities of Captopril.
CaptoprilThe serum concentration of Alfuzosin can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Alfuzosin can be increased when combined with Carbamazepine.
CarteololAlfuzosin may increase the hypotensive activities of Carteolol.
CarteololCarteolol may increase the orthostatic hypotensive activities of Alfuzosin.
CarvedilolAlfuzosin may increase the antihypertensive activities of Carvedilol.
CeliprololAlfuzosin may increase the hypotensive activities of Celiprolol.
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Alfuzosin.
CeritinibThe serum concentration of Alfuzosin can be increased when it is combined with Ceritinib.
CeritinibAlfuzosin may increase the QTc-prolonging activities of Ceritinib.
ChloroquineAlfuzosin may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideAlfuzosin may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineAlfuzosin may increase the QTc-prolonging activities of Chlorpromazine.
ChlorthalidoneAlfuzosin may increase the hypotensive activities of Chlorthalidone.
ChymostatinThe serum concentration of Alfuzosin can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Alfuzosin can be increased when it is combined with Cilastatin.
CilazaprilAlfuzosin may increase the hypotensive activities of Cilazapril.
CilazaprilThe serum concentration of Alfuzosin can be increased when it is combined with Cilazapril.
CilnidipineAlfuzosin may increase the hypotensive activities of Cilnidipine.
CinnarizineAlfuzosin may increase the hypotensive activities of Cinnarizine.
CiprofloxacinAlfuzosin may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineAlfuzosin may decrease the vasoconstricting activities of Cirazoline.
CisaprideAlfuzosin may increase the QTc-prolonging activities of Cisapride.
CitalopramAlfuzosin may increase the QTc-prolonging activities of Citalopram.
ClarithromycinThe serum concentration of Alfuzosin can be increased when it is combined with Clarithromycin.
ClarithromycinAlfuzosin may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Alfuzosin can be decreased when combined with Clemastine.
ClevidipineAlfuzosin may increase the hypotensive activities of Clevidipine.
ClonidineAlfuzosin may increase the hypotensive activities of Clonidine.
ClotrimazoleThe metabolism of Alfuzosin can be decreased when combined with Clotrimazole.
ClozapineAlfuzosin may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Alfuzosin can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Alfuzosin can be increased when it is combined with Conivaptan.
CrizotinibAlfuzosin may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Alfuzosin can be decreased when combined with Crizotinib.
CryptenamineAlfuzosin may increase the hypotensive activities of Cryptenamine.
CyclosporineThe metabolism of Alfuzosin can be decreased when combined with Cyclosporine.
CyclothiazideAlfuzosin may increase the hypotensive activities of Cyclothiazide.
Dabigatran etexilateThe serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Alfuzosin can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Alfuzosin.
DarodipineAlfuzosin may increase the hypotensive activities of Darodipine.
DarunavirThe serum concentration of Alfuzosin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Alfuzosin can be increased when it is combined with Dasatinib.
DebrisoquinAlfuzosin may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Alfuzosin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Alfuzosin can be decreased when combined with Delavirdine.
DeserpidineAlfuzosin may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Alfuzosin can be decreased when it is combined with Dexamethasone.
DiazoxideAlfuzosin may increase the hypotensive activities of Diazoxide.
DihydroergotamineThe metabolism of Alfuzosin can be decreased when combined with Dihydroergotamine.
DiltiazemAlfuzosin may increase the hypotensive activities of Diltiazem.
DiltiazemThe metabolism of Alfuzosin can be decreased when combined with Diltiazem.
DisopyramideAlfuzosin may increase the QTc-prolonging activities of Disopyramide.
DofetilideAlfuzosin may increase the QTc-prolonging activities of Dofetilide.
DolasetronAlfuzosin may increase the QTc-prolonging activities of Dolasetron.
DomperidoneAlfuzosin may increase the QTc-prolonging activities of Domperidone.
DorzolamideAlfuzosin may increase the hypotensive activities of Dorzolamide.
DotarizineAlfuzosin may increase the hypotensive activities of Dotarizine.
DoxazosinAlfuzosin may increase the antihypertensive activities of Doxazosin.
DoxycyclineThe metabolism of Alfuzosin can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Alfuzosin can be decreased when combined with Dronedarone.
DronedaroneAlfuzosin may increase the QTc-prolonging activities of Dronedarone.
DroperidolAlfuzosin may increase the QTc-prolonging activities of Droperidol.
EcabetThe serum concentration of Alfuzosin can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Alfuzosin can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Alfuzosin can be decreased when it is combined with Efavirenz.
EfonidipineAlfuzosin may increase the hypotensive activities of Efonidipine.
ElafinThe serum concentration of Alfuzosin can be increased when it is combined with Elafin.
EliglustatAlfuzosin may increase the QTc-prolonging activities of Eliglustat.
EnalaprilAlfuzosin may increase the hypotensive activities of Enalapril.
EnalaprilThe serum concentration of Alfuzosin can be increased when it is combined with Enalapril.
EnalaprilatAlfuzosin may increase the hypotensive activities of Enalaprilat.
EnalaprilatThe serum concentration of Alfuzosin can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Alfuzosin can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide.
EperisoneAlfuzosin may increase the hypotensive activities of Eperisone.
EpoprostenolAlfuzosin may increase the hypotensive activities of Epoprostenol.
EprosartanAlfuzosin may increase the hypotensive activities of Eprosartan.
ErgotamineAlfuzosin may decrease the vasoconstricting activities of Ergotamine.
ErythromycinAlfuzosin may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Alfuzosin can be decreased when combined with Erythromycin.
EscitalopramAlfuzosin may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Alfuzosin can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the orthostatic hypotensive activities of Alfuzosin.
EtravirineThe serum concentration of Alfuzosin can be decreased when it is combined with Etravirine.
FelodipineAlfuzosin may increase the hypotensive activities of Felodipine.
FendilineAlfuzosin may increase the hypotensive activities of Fendiline.
FenoldopamAlfuzosin may increase the hypotensive activities of Fenoldopam.
FlecainideAlfuzosin may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Alfuzosin can be decreased when combined with Fluconazole.
FlunarizineAlfuzosin may increase the hypotensive activities of Flunarizine.
FluoxetineAlfuzosin may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolAlfuzosin may increase the QTc-prolonging activities of Flupentixol.
FluvoxamineThe metabolism of Alfuzosin can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Alfuzosin can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Alfuzosin can be increased when it is combined with Fosaprepitant.
FosinoprilAlfuzosin may increase the hypotensive activities of Fosinopril.
FosinoprilThe serum concentration of Alfuzosin can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Alfuzosin can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Alfuzosin can be increased when it is combined with Fusidic Acid.
GabapentinAlfuzosin may increase the hypotensive activities of Gabapentin.
Gadobenic acidAlfuzosin may increase the QTc-prolonging activities of Gadobenic acid.
GeldanamycinThe serum concentration of Alfuzosin can be increased when it is combined with Geldanamycin.
GemifloxacinAlfuzosin may increase the QTc-prolonging activities of Gemifloxacin.
GM6001The serum concentration of Alfuzosin can be increased when it is combined with GM6001.
GoserelinAlfuzosin may increase the QTc-prolonging activities of Goserelin.
GranisetronAlfuzosin may increase the QTc-prolonging activities of Granisetron.
GuanabenzAlfuzosin may increase the hypotensive activities of Guanabenz.
GuanadrelAlfuzosin may increase the hypotensive activities of Guanadrel.
GuanethidineAlfuzosin may increase the hypotensive activities of Guanethidine.
GuanfacineAlfuzosin may increase the hypotensive activities of Guanfacine.
HaloperidolAlfuzosin may increase the QTc-prolonging activities of Haloperidol.
HexamethoniumAlfuzosin may increase the hypotensive activities of Hexamethonium.
HirulogThe serum concentration of Alfuzosin can be increased when it is combined with Hirulog.
HydralazineAlfuzosin may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideAlfuzosin may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideAlfuzosin may increase the hypotensive activities of Hydroflumethiazide.
IbutilideAlfuzosin may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Alfuzosin can be increased when it is combined with Idelalisib.
IloperidoneAlfuzosin may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Alfuzosin can be decreased when combined with Imatinib.
IndapamideAlfuzosin may increase the hypotensive activities of Indapamide.
IndenololAlfuzosin may increase the hypotensive activities of Indenolol.
IndenololIndenolol may increase the orthostatic hypotensive activities of Alfuzosin.
IndinavirThe serum concentration of Alfuzosin can be increased when it is combined with Indinavir.
IndoraminAlfuzosin may increase the antihypertensive activities of Indoramin.
IrbesartanAlfuzosin may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Alfuzosin can be decreased when combined with Isavuconazonium.
IsoflurophateThe serum concentration of Alfuzosin can be increased when it is combined with Isoflurophate.
IsradipineAlfuzosin may increase the hypotensive activities of Isradipine.
IsradipineThe metabolism of Alfuzosin can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Alfuzosin can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Alfuzosin can be increased when it is combined with Ixazomib.
KetoconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Ketoconazole.
LabetalolAlfuzosin may increase the antihypertensive activities of Labetalol.
LacidipineAlfuzosin may increase the hypotensive activities of Lacidipine.
LamotrigineAlfuzosin may increase the hypotensive activities of Lamotrigine.
LatanoprostAlfuzosin may increase the hypotensive activities of Latanoprost.
LenvatinibAlfuzosin may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Alfuzosin can be increased when it is combined with Lepirudin.
LercanidipineAlfuzosin may increase the hypotensive activities of Lercanidipine.
LeuprolideAlfuzosin may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinAlfuzosin may increase the QTc-prolonging activities of Levofloxacin.
LinagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Linagliptin.
LisinoprilAlfuzosin may increase the hypotensive activities of Lisinopril.
LisinoprilThe serum concentration of Alfuzosin can be increased when it is combined with Lisinopril.
LofexidineAlfuzosin may increase the hypotensive activities of Lofexidine.
LopinavirThe serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.
LopinavirAlfuzosin may increase the QTc-prolonging activities of Lopinavir.
LosartanAlfuzosin may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Alfuzosin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Luliconazole.
LumefantrineAlfuzosin may increase the QTc-prolonging activities of Lumefantrine.
MacitentanAlfuzosin may increase the hypotensive activities of Macitentan.
Magnesium SulfateAlfuzosin may increase the hypotensive activities of Magnesium Sulfate.
ManidipineAlfuzosin may increase the hypotensive activities of Manidipine.
MecamylamineAlfuzosin may increase the hypotensive activities of Mecamylamine.
MephentermineAlfuzosin may decrease the vasoconstricting activities of Mephentermine.
MetaraminolAlfuzosin may decrease the vasoconstricting activities of Metaraminol.
MethadoneAlfuzosin may increase the QTc-prolonging activities of Methadone.
MethoxamineAlfuzosin may decrease the vasoconstricting activities of Methoxamine.
MethyldopaAlfuzosin may increase the hypotensive activities of Methyldopa.
MetipranololAlfuzosin may increase the hypotensive activities of Metipranolol.
MetolazoneAlfuzosin may increase the hypotensive activities of Metolazone.
MetoprololAlfuzosin may increase the hypotensive activities of Metoprolol.
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Alfuzosin.
MibefradilAlfuzosin may increase the hypotensive activities of Mibefradil.
MidodrineAlfuzosin may decrease the vasoconstricting activities of Midodrine.
MifepristoneThe metabolism of Alfuzosin can be decreased when combined with Mifepristone.
MifepristoneAlfuzosin may increase the QTc-prolonging activities of Mifepristone.
MinoxidilAlfuzosin may increase the hypotensive activities of Minoxidil.
MitotaneThe serum concentration of Alfuzosin can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Alfuzosin can be decreased when it is combined with Modafinil.
MoexiprilAlfuzosin may increase the hypotensive activities of Moexipril.
MoexiprilThe serum concentration of Alfuzosin can be increased when it is combined with Moexipril.
MoxifloxacinAlfuzosin may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineAlfuzosin may increase the hypotensive activities of Moxonidine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Alfuzosin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololAlfuzosin may increase the hypotensive activities of Nadolol.
NadololNadolol may increase the orthostatic hypotensive activities of Alfuzosin.
NafcillinThe serum concentration of Alfuzosin can be decreased when it is combined with Nafcillin.
NCX 4016The serum concentration of Alfuzosin can be increased when it is combined with NCX 4016.
NebivololAlfuzosin may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Alfuzosin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Alfuzosin can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Alfuzosin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Alfuzosin can be decreased when combined with Nevirapine.
NicardipineAlfuzosin may increase the hypotensive activities of Nicardipine.
NicorandilAlfuzosin may increase the hypotensive activities of Nicorandil.
NifedipineAlfuzosin may increase the hypotensive activities of Nifedipine.
NiguldipineAlfuzosin may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Alfuzosin can be decreased when combined with Nilotinib.
NilotinibAlfuzosin may increase the QTc-prolonging activities of Nilotinib.
NiludipineAlfuzosin may increase the hypotensive activities of Niludipine.
NilvadipineAlfuzosin may increase the hypotensive activities of Nilvadipine.
NimesulideAlfuzosin may increase the hypotensive activities of Nimesulide.
NimodipineAlfuzosin may increase the hypotensive activities of Nimodipine.
NisoldipineAlfuzosin may increase the hypotensive activities of Nisoldipine.
NitrendipineAlfuzosin may increase the hypotensive activities of Nitrendipine.
NitroglycerinAlfuzosin may increase the hypotensive activities of Nitroglycerin.
NitroprussideAlfuzosin may increase the hypotensive activities of Nitroprusside.
OfloxacinAlfuzosin may increase the QTc-prolonging activities of Ofloxacin.
OlaparibThe metabolism of Alfuzosin can be decreased when combined with Olaparib.
OlmesartanAlfuzosin may increase the hypotensive activities of Olmesartan.
OmapatrilatAlfuzosin may increase the hypotensive activities of Omapatrilat.
OmapatrilatThe serum concentration of Alfuzosin can be increased when it is combined with Omapatrilat.
OndansetronAlfuzosin may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Alfuzosin can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Alfuzosin can be increased when it is combined with Otamixaban.
OxprenololAlfuzosin may increase the hypotensive activities of Oxprenolol.
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Alfuzosin.
PalbociclibThe serum concentration of Alfuzosin can be increased when it is combined with Palbociclib.
PaliperidoneAlfuzosin may increase the QTc-prolonging activities of Paliperidone.
PanobinostatAlfuzosin may increase the QTc-prolonging activities of Panobinostat.
PargylineAlfuzosin may increase the hypotensive activities of Pargyline.
PazopanibAlfuzosin may increase the QTc-prolonging activities of Pazopanib.
PenbutololAlfuzosin may increase the hypotensive activities of Penbutolol.
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Alfuzosin.
PentamidineAlfuzosin may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Alfuzosin can be increased when combined with Pentobarbital.
PentoliniumAlfuzosin may increase the hypotensive activities of Pentolinium.
PerflutrenAlfuzosin may increase the QTc-prolonging activities of Perflutren.
PerhexilineAlfuzosin may increase the hypotensive activities of Perhexiline.
PerindoprilAlfuzosin may increase the hypotensive activities of Perindopril.
PerindoprilThe serum concentration of Alfuzosin can be increased when it is combined with Perindopril.
PhenobarbitalThe metabolism of Alfuzosin can be increased when combined with Phenobarbital.
PhenoxybenzamineAlfuzosin may increase the hypotensive activities of Phenoxybenzamine.
PhentolamineAlfuzosin may increase the hypotensive activities of Phentolamine.
PhenylephrineAlfuzosin may decrease the vasoconstricting activities of Phenylephrine.
PhenytoinThe metabolism of Alfuzosin can be increased when combined with Phenytoin.
PhosphoramidonThe serum concentration of Alfuzosin can be increased when it is combined with Phosphoramidon.
PimozideAlfuzosin may increase the QTc-prolonging activities of Pimozide.
PinacidilAlfuzosin may increase the hypotensive activities of Pinacidil.
PinaveriumAlfuzosin may increase the hypotensive activities of Pinaverium.
PindololAlfuzosin may increase the hypotensive activities of Pindolol.
PindololPindolol may increase the orthostatic hypotensive activities of Alfuzosin.
PolythiazideAlfuzosin may increase the hypotensive activities of Polythiazide.
PosaconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Posaconazole.
PractololPractolol may increase the orthostatic hypotensive activities of Alfuzosin.
PrazosinAlfuzosin may increase the antihypertensive activities of Prazosin.
PregabalinAlfuzosin may increase the hypotensive activities of Pregabalin.
PrenylamineAlfuzosin may increase the hypotensive activities of Prenylamine.
PrimaquineAlfuzosin may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Alfuzosin can be increased when combined with Primidone.
PrinomastatThe serum concentration of Alfuzosin can be increased when it is combined with Prinomastat.
ProcainamideAlfuzosin may increase the QTc-prolonging activities of Procainamide.
PromazineAlfuzosin may increase the QTc-prolonging activities of Promazine.
PropafenoneAlfuzosin may increase the QTc-prolonging activities of Propafenone.
PropranololAlfuzosin may increase the hypotensive activities of Propranolol.
PropranololPropranolol may increase the orthostatic hypotensive activities of Alfuzosin.
QuetiapineAlfuzosin may increase the QTc-prolonging activities of Quetiapine.
QuinaprilAlfuzosin may increase the hypotensive activities of Quinapril.
QuinaprilThe serum concentration of Alfuzosin can be increased when it is combined with Quinapril.
QuinidineAlfuzosin may increase the QTc-prolonging activities of Quinidine.
QuinineAlfuzosin may increase the QTc-prolonging activities of Quinine.
RamiprilAlfuzosin may increase the hypotensive activities of Ramipril.
RamiprilThe serum concentration of Alfuzosin can be increased when it is combined with Ramipril.
RanolazineThe metabolism of Alfuzosin can be decreased when combined with Ranolazine.
RemikirenAlfuzosin may increase the hypotensive activities of Remikiren.
RemikirenThe serum concentration of Alfuzosin can be increased when it is combined with Remikiren.
RescinnamineAlfuzosin may increase the hypotensive activities of Rescinnamine.
ReserpineAlfuzosin may increase the hypotensive activities of Reserpine.
RifabutinThe metabolism of Alfuzosin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Alfuzosin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Alfuzosin can be increased when combined with Rifapentine.
RiociguatAlfuzosin may increase the hypotensive activities of Riociguat.
RisedronateAlfuzosin may increase the hypotensive activities of Risedronate.
RitonavirThe serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Alfuzosin can be increased when it is combined with Rivaroxaban.
SaprisartanAlfuzosin may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Alfuzosin can be increased when it is combined with Saquinavir.
SaquinavirAlfuzosin may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Saxagliptin.
SelexipagAlfuzosin may increase the hypotensive activities of Selexipag.
SildenafilThe metabolism of Alfuzosin can be decreased when combined with Sildenafil.
SilodosinAlfuzosin may increase the antihypertensive activities of Silodosin.
SiltuximabThe serum concentration of Alfuzosin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Alfuzosin can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Sitagliptin.
SitaxentanAlfuzosin may increase the hypotensive activities of Sitaxentan.
SotalolSotalol may increase the orthostatic hypotensive activities of Alfuzosin.
SotalolAlfuzosin may increase the QTc-prolonging activities of Sotalol.
SpiraprilAlfuzosin may increase the hypotensive activities of Spirapril.
SpiraprilThe serum concentration of Alfuzosin can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Alfuzosin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Alfuzosin can be increased when it is combined with Stiripentol.
SulfisoxazoleAlfuzosin may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Alfuzosin can be decreased when combined with Sulfisoxazole.
TadalafilTadalafil may increase the hypotensive activities of Alfuzosin.
TamsulosinAlfuzosin may increase the antihypertensive activities of Tamsulosin.
TelaprevirThe serum concentration of Alfuzosin can be increased when it is combined with Telaprevir.
TelavancinAlfuzosin may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Alfuzosin can be increased when it is combined with Telithromycin.
TelithromycinAlfuzosin may increase the QTc-prolonging activities of Telithromycin.
TelmisartanAlfuzosin may increase the hypotensive activities of Telmisartan.
TemocaprilAlfuzosin may increase the hypotensive activities of Temocapril.
TemocaprilThe serum concentration of Alfuzosin can be increased when it is combined with Temocapril.
TerazosinAlfuzosin may increase the antihypertensive activities of Terazosin.
TerlipressinAlfuzosin may increase the hypotensive activities of Terlipressin.
TetrabenazineAlfuzosin may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineAlfuzosin may increase the QTc-prolonging activities of Thioridazine.
ThiorphanThe serum concentration of Alfuzosin can be increased when it is combined with Thiorphan.
TiboloneAlfuzosin may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Alfuzosin can be decreased when combined with Ticlopidine.
TicrynafenAlfuzosin may increase the hypotensive activities of Ticrynafen.
TimololAlfuzosin may increase the hypotensive activities of Timolol.
TimololTimolol may increase the orthostatic hypotensive activities of Alfuzosin.
TipranavirThe serum concentration of Alfuzosin can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Alfuzosin can be decreased when it is combined with Tocilizumab.
TolazolineAlfuzosin may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidAlfuzosin may increase the hypotensive activities of Tolfenamic Acid.
TorasemideAlfuzosin may increase the hypotensive activities of Torasemide.
ToremifeneAlfuzosin may increase the QTc-prolonging activities of Toremifene.
TrandolaprilAlfuzosin may increase the hypotensive activities of Trandolapril.
TrandolaprilThe serum concentration of Alfuzosin can be increased when it is combined with Trandolapril.
TranilastAlfuzosin may increase the hypotensive activities of Tranilast.
TravoprostAlfuzosin may increase the hypotensive activities of Travoprost.
TreprostinilAlfuzosin may increase the hypotensive activities of Treprostinil.
TrichlormethiazideAlfuzosin may increase the hypotensive activities of Trichlormethiazide.
TrimazosinAlfuzosin may increase the antihypertensive activities of Trimazosin.
TrimethaphanAlfuzosin may increase the hypotensive activities of Trimethaphan.
UbenimexThe serum concentration of Alfuzosin can be increased when it is combined with Ubenimex.
UdenafilUdenafil may increase the hypotensive activities of Alfuzosin.
UnoprostoneAlfuzosin may increase the hypotensive activities of Unoprostone.
ValsartanAlfuzosin may increase the hypotensive activities of Valsartan.
VandetanibAlfuzosin may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the hypotensive activities of Alfuzosin.
VemurafenibAlfuzosin may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Alfuzosin can be decreased when combined with Venlafaxine.
VerapamilAlfuzosin may increase the hypotensive activities of Verapamil.
VerapamilThe metabolism of Alfuzosin can be decreased when combined with Verapamil.
VildagliptinThe serum concentration of Alfuzosin can be increased when it is combined with Vildagliptin.
VoriconazoleThe serum concentration of Alfuzosin can be increased when it is combined with Voriconazole.
XimelagatranThe serum concentration of Alfuzosin can be increased when it is combined with Ximelagatran.
XylometazolineAlfuzosin may increase the hypotensive activities of Xylometazoline.
ZiconotideAlfuzosin may increase the hypotensive activities of Ziconotide.
ZiprasidoneThe metabolism of Alfuzosin can be decreased when combined with Ziprasidone.
ZiprasidoneAlfuzosin may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolAlfuzosin may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take after a meal (always the same meal), product bioavailability is reduced when taken on an empty stomach.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556 ]
  3. Lee M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39. [PubMed:12892027 ]
  4. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  5. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685 ]
  6. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35. [PubMed:9223558 ]
  7. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478 ]
  8. Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62. [PubMed:9870119 ]
  9. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526 ]
  10. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  11. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556 ]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  4. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685 ]
  5. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478 ]
  6. Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62. [PubMed:9870119 ]
  7. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526 ]
  8. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  9. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556 ]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  4. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685 ]
  5. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478 ]
  6. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526 ]
  7. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  8. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Derek Chadwick, Jamie Goode (2005). The HERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome, Novartis Foundation Symposium. Wiley. [ISBN:0470021411 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Guay DR: Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23. [PubMed:15555475 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38